135 related articles for article (PubMed ID: 38315477)
1. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
Petersen CL; Hougaard A; Gaist D; Hallas J
JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
[TBL] [Abstract][Full Text] [Related]
2. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
[TBL] [Abstract][Full Text] [Related]
3. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
[TBL] [Abstract][Full Text] [Related]
4. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
[TBL] [Abstract][Full Text] [Related]
5. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
[TBL] [Abstract][Full Text] [Related]
6. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.
Hall GC; Brown MM; Mo J; MacRae KD
Neurology; 2004 Feb; 62(4):563-8. PubMed ID: 14981171
[TBL] [Abstract][Full Text] [Related]
7. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
[TBL] [Abstract][Full Text] [Related]
8. Triptan use as a function of cardiovascular risk. A population-based study.
Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
[TBL] [Abstract][Full Text] [Related]
9. Twenty-five years of triptans - a nationwide population study.
Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
[TBL] [Abstract][Full Text] [Related]
10. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
11. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E
Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519
[TBL] [Abstract][Full Text] [Related]
12. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
13. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
14. Low adherence to the guideline for the acute treatment of migraine.
Olesen A; Schytz HW; Ostrowski SR; Topholm M; Nielsen K; Erikstrup C; Mikkelsen S; Pedersen OB; Olesen J; Hansen TF; Chalmer MA
Sci Rep; 2022 May; 12(1):8487. PubMed ID: 35589944
[TBL] [Abstract][Full Text] [Related]
15. Severe vascular events in migraine patients.
Velentgas P; Cole JA; Mo J; Sikes CR; Walker AM
Headache; 2004; 44(7):642-51. PubMed ID: 15209685
[TBL] [Abstract][Full Text] [Related]
16. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study.
Wood ME; Lapane K; Frazier JA; Ystrom E; Mick EO; Nordeng H
Paediatr Perinat Epidemiol; 2016 Mar; 30(2):190-200. PubMed ID: 26525300
[TBL] [Abstract][Full Text] [Related]
17. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
18. Risk of Stroke in Migraineurs Using Triptans. Associations with Age, Sex, Stroke Severity and Subtype.
Albieri V; Olsen TS; Andersen KK
EBioMedicine; 2016 Apr; 6():199-205. PubMed ID: 27211561
[TBL] [Abstract][Full Text] [Related]
19. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
20. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
